Erebra - for specialists

  • Mechanism of action
  • Publications
  • Efficiency and safety

Mechanism of action

Erebra® is a broad-spectrum antiviral drug
Erebra's clinical efficacy has been attributed to its ability to block neuraminidase.
Influenza virus structure

Neuraminidase (HA) is a glycoprotein complex with enzymatic activity.


The outer layer is a lipid membrane taken from the host cell in which the virus replicated.

The viral or matrix protein M1 is located in the lipid membrane. This protein fills the envelope of the virus, gives it stability and rigidity.

Inside the virion there are viral RNAs: in influenza A and B viruses there are eight, in influenza C - seven.

Above two types of «spikes» (glycoproteins) - hemagglutinin (HA) and neuraminidase (NA) - surface antigens of the influenza virus rise up by the envelope of the virus.

H and N determine the type and subtype of the influenza virus (for example, A / H1N1).

Hemagglutinin (HA) is a polypeptide called due to the ability to hemolysis erythrocytes.

HA has high variability and immunogenicity, ensuring the attachment of the virus to the cell.

The intensity of intoxication with influenza is determined precisely by the properties of hemagglutinins.

Viral neuraminidase (NA) is necessary in order to release viral particles by cleaving hemagglutinin receptors on which daughter viruses can adhere.

In addition, the released virus particles can form non-viable clusters, due to the fact that they carry on its surface there are remnants of a cell membrane. NA cleaves them, increasing the ability of influenza viruses to infect new cells.

NA helps the virus to penetrate the mucous membranes by breaking down neuraminic acids in the mucus of the respiratory tract

In addition, NA has a pronounced immunosuppressive effect.


Erebra® binds to the active site of the viral NA, thereby blocking its activity.

When NA is suppressed, the ability of viruses to penetrate into sensitive cells is impaired, and the release of the virus is inhibited from the infected cell and the resistance of the pathogen to the inactivating action of the mucous secretions of the respiratory tract decreases, as a result of which the further spread of the virus in the body stops.

In addition, NA inhibitors, including Erebra®, reduce the production of certain cytokines, preventing the development of a local inflammatory reaction and weakening the systemic manifestations of a viral infection (fever, etc.)

Erebra® has antibacterial and antifungal activity against: Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Mycobacterium tuberculosis, Microsporum canis, Candida albicans.

Erebra® promotes correction ration of cellular immunity and increases the content of serum interferon

Erebra® regulates FRO processes due to both direct radical interfering activity against lipid radicals and indirect antioxidant properties